• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

BCBSNC Invests in Prime Therapeutics

Article

Prime Therapeutics (Prime) will administer pharmacy benefits for Blue Cross and Blue Shield of North Carolina (BCBSNC) commercial customers staring in April next year. The companies say the move will result in lower pharmacy costs for BCBSNC customers and more flexibility regarding services and programs.

Prime Therapeutics (Prime) will administer pharmacy benefits for Blue Cross and Blue Shield of North Carolina (BCBSNC) commercial customers staring in April next year. The companies say the move will result in lower pharmacy costs for BCBSNC customers and more flexibility regarding services and programs.

Prime is a privately held pharmacy benefits management (PBM) company that is owned by nine Blue organizations representing 12 plans. BCBSNC intends to purchase an equity interest in Prime Therapeutics so it will have input and insight into Prime Therapeutics’ operations, and will be better able to coordinate pharmacy and health management programs.

BCBSNC expects the investment to help them lower costs in preparation for future healthcare changes.

“We will be able to utilize resources through Prime to offer products that meet the needs of our ASO (administrative services only) customers as well as our underwritten membership at a lower administration cost,” says BCBSNC’s Director of Pharmacy Programs Estay Greene.

Prime Therapeutics serves nearly 19 million customers across the U.S. via claims processing, formulary management, mail service, pharmacy network management, manufacturer trade contracting and clinical programs. BCBSNC serves more than 3.7 million members, including approximately 900,000 served on behalf of other Blue Plans.

Go back to the Managed Healthcare Executive eNews newsletter.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.